03 January 2023: Original Paper
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China
Jing Liu 1BCDEF* , Haitao Wang 1BCDF* , Xiaohong Li 1B , Yamei Wu 1B , Yuanyuan Ma 1B , Zhenyang Gu 1B , Fei Li 1B , Meng Li 1BD , Jiayuan Guo 2B , Yu Zhao 1B , Quanshun Wang 1B , Jian Bo 1B , Wenrong Huang 1B , Liping Dou 1BD , Yuanbo Liu 3AEF , Daihong Liu 1BD , Xiaoxiong Wu 1ADF* , Chunji Gao 1ADEFG*DOI: 10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
Table 1 Clinical Characteristics of PCNSL patients.
| Total (n=47) | ASCT (n=20) | No ASCT (n=27) | p value | |
|---|---|---|---|---|
| Age | 0.095 | |||
| Median age (range) | 51 (21–77) | 47.5 (21–62) | 57 (26–77) | |
| ≥60 | 13 (27.7) | 3 (15.0) | 10 (37.0) | |
| 34 (72.3) | 17 (85.0) | 17 (63.0) | ||
| Gender | 0.210 | |||
| Male | 28 (59.6) | 14 (70.0) | 14 (51.9) | |
| Female | 19 (40.4) | 6 (30.0) | 13 (48.1) | |
| ECOG performance status | 0.808 | |||
| 0 to 1 | 15 (31.9) | 6 (30.0) | 9 (33.3) | |
| At least 2 | 32 (68.1) | 14 (70.0) | 18 (66.7) | |
| Number of lesions | 0.696 | |||
| 1 | 15 (31.9) | 7 (35.0) | 8 (29.6) | |
| At least 2 | 32 (68.1) | 13 (65.0) | 19 (70.4) | |
| Deep involvement | 0.266 | |||
| Presence | 38 (80.9) | 18 (90.0) | 20 (74.1) | |
| Absence | 9 (19.1) | 2 (10.0) | 7 (25.9) | |
| Diagnostic methods | 0.428 | |||
| Surgery | 14 (29.8) | 7 (35.0) | 7 (25.9) | |
| Stereotactic biopsy | 32 (68.1) | 12 (60.0) | 20 (74.1) | |
| Brain MRI | 1 (2.1) | 1 (5.0) | 0 (0.0) | |
| Pathology | 0.958 | |||
| DLBCL | 45 (95.7) | 19 (95.0) | 26 (96.3) | |
| GCB | 9 (19.1) | 4 (20.0) | 5 (18.5) | |
| Non-GCB | 27 (57.4) | 12 (60.0) | 15 (55.6) | |
| Unclassified | 9 (19.2) | 3 (15.0) | 6 (22.2) | |
| Unknown | 2 (4.3) | 1 (5.0) | 1 (3.7) | |
| Induction therapy | _ | |||
| (R)M | 19 (40.4) | 12 (60.0) | 7 (30.0) | |
| (R)MAID | 14 (29.8) | 3 (15.0) | 11 (40.7) | |
| (R)MT | 3 (6.4) | 3 (15.0) | 0 (0.0) | |
| RMA | 3 (6.4) | 2 (10.0) | 1 (3.7) | |
| R2M | 6 (12.8) | 0 (0.0) | 6 (22.2) | |
| IRM | 2 (4.2) | 0 (0.0) | 2 (7.4) | |
| Early response | 0.114 | |||
| OR | 39 (83.0) | 19 (95.0) | 20 (74.1) | |
| CR | 33 (70.2) | 18 (90.0) | 15 (55.6) | |
| PR | 6 (12.8) | 1 (5.0) | 5 (18.5) | |
| SD/PD | 8 (17.0) | 1 (5.0) | 7 (25.9) | |
| ECOG – Eastern Cooperative Oncology Group; DLBCL – diffuse large B cell lymphoma; GCB – germinal center B-cell-like; (R)M – methotrexate with or without rituximab; (R)MAID – methotrexate + cytarabine + idarubicin + dexamethasone with or without rituximab; (R)MT – methotrexate and temozolomide with or without rituximab; RMA – rituximab + methotrexate + cytarabine; R2M – methotrexate + rituximab + lenalidomide; IRM – methotrexate + ibrutinib + rituximab; OR – overall resonse; CR – complete remission; PR – partial response; SD – stable disease; PD – progression disease. | ||||